Frederick Corsentino - BIO Key Chief Revenue Officer
| BKYI Stock | USD 0.84 0.02 2.33% |
Executive
Mr. Frederick Corsentino is Chief Revenue Officer of the Company. Mr. Corsentino launched a consulting practice that advises security and information research and technology companies on goto market strategies to increase sales prospects and drive revenue growth. He also recently served as Chief Revenue Officer at Comodo, a cyber security provider, where he managed the sales team and successfully launched a new line of end point protection and cloud computing security products. From 2005 to 2007 he led sales at Meru Networks, a WiFi networking company, growing worldwide revenues from 1M to 40M in two years. This sales trajectory helped pave the way to the Company IPO and the Company was acquired by Fortinet in 2015 since 2018.
| Age | 57 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 101 Crawfords Corner Road, Holmdel, NJ, United States, 07753 |
| Phone | 732 359 1100 |
| Web | https://www.bio-key.com |
BIO Key Management Efficiency
The company has return on total asset (ROA) of (0.5568) % which means that it has lost $0.5568 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.5811) %, meaning that it created substantial loss on money invested by shareholders. BIO Key's management efficiency ratios could be used to measure how well BIO Key manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -2.88. The BIO Key's current Return On Capital Employed is estimated to increase to -6.43. As of now, BIO Key's Intangibles To Total Assets are decreasing as compared to previous years. The BIO Key's current Fixed Asset Turnover is estimated to increase to 31.17, while Total Assets are projected to decrease to under 4.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| DeLu Jackson | ADT Inc | 51 | |
| Alicia Kelly | Senstar Technologies | 46 | |
| David EdD | CoreCivic | 60 | |
| Michael Grant | CoreCivic | N/A | |
| Kenneth Hoskins | LogicMark | N/A | |
| Aaron Lehnhardt | Knightscope | 51 | |
| Stacy Stephens | Knightscope | 52 | |
| David Scott | ADT Inc | 50 | |
| Gillon Beck | Senstar Technologies | 62 | |
| Jason Gonzalez | Knightscope | N/A | |
| Garett Hunter | LogicMark | N/A | |
| Yuting Zuo | Guardforce AI Co | 32 | |
| Fabien Haubert | Senstar Technologies | 48 | |
| Lucibeth JD | CoreCivic | 52 | |
| Mercedes Soria | Knightscope | 50 | |
| Ronald Gallegos | Knightscope | N/A | |
| Steve MBA | CoreCivic | N/A | |
| Wayne Thorsen | ADT Inc | 51 | |
| Peter Weinberg | Knightscope | 63 | |
Management Performance
| Return On Equity | -4.58 | ||||
| Return On Asset | -0.56 |
BIO Key International Leadership Team
Elected by the shareholders, the BIO Key's board of directors comprises two types of representatives: BIO Key inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BIO. The board's role is to monitor BIO Key's management team and ensure that shareholders' interests are well served. BIO Key's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BIO Key's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Cochran, President PortalGuard | ||
| Cecilia Welch, Chief Officer | ||
| Akintunde Jeje, Managing Africa | ||
| Alex Rocha, Managing EMEA | ||
| Mira LaCous, Chief Officer | ||
| Kwok Wong, MD ViceChairman | ||
| Michael DePasquale, Chairman, CEO and Pres | ||
| Frederick Corsentino, Chief Revenue Officer | ||
| James Sullivan, Senior Officer |
BIO Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BIO Key a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.58 | ||||
| Return On Asset | -0.56 | ||||
| Profit Margin | (0.92) % | ||||
| Operating Margin | (1.45) % | ||||
| Current Valuation | 3.29 M | ||||
| Shares Outstanding | 3.11 M | ||||
| Shares Owned By Insiders | 5.57 % | ||||
| Shares Owned By Institutions | 5.02 % | ||||
| Number Of Shares Shorted | 865.18 K | ||||
| Price To Earning | (2.55) X |
Currently Active Assets on Macroaxis
When determining whether BIO Key International offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BIO Key's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Key International Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Key International Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BIO Key International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Systems Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BIO Key. If investors know BIO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BIO Key listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.66) | Revenue Per Share 6.323 | Quarterly Revenue Growth (0.41) | Return On Assets (0.56) | Return On Equity (4.58) |
The market value of BIO Key International is measured differently than its book value, which is the value of BIO that is recorded on the company's balance sheet. Investors also form their own opinion of BIO Key's value that differs from its market value or its book value, called intrinsic value, which is BIO Key's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BIO Key's market value can be influenced by many factors that don't directly affect BIO Key's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BIO Key's value and its price as these two are different measures arrived at by different means. Investors typically determine if BIO Key is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BIO Key's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.